• Validated HPLC-MS, NMR and a validated cell-based biological potency assay using the U937 human cell line, with MIP-1β as a biological marker of Thykamine™’s anti-inflammatory activity, provide complementary chemical and biological measures of Thykamine™ and demonstrate reliable batch-to-batch consistency.

Devonian Health Group Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announced the successful independent validation and integration of key analytical and biological quality-control technologies into the extraction and manufacturing process for Thykamine™, the Company’s lead active botanical drug candidate.

The Company’s quality-control strategy combines validated High-Performance Liquid Chromatography coupled with Mass Spectrometry (“HPLC-MS“) chemical fingerprinting, Nuclear Magnetic Resonance (“NMR“) spectroscopy and a validated cell-based biological potency assay using the U937 human cell line to measure macrophage inflammatory protein-1 beta (“MIP-1β“) as a biological marker of Thykamine™’s anti-inflammatory activity.

The HPLC-MS analytical method has been independently validated by U.S.-based Chromak Research Inc., while the U-937 cell-based biological potency assay has been independently validated by U.S.-based Pacific BioLabs. Both validated methodologies have been integrated into Devonian’s Quality Assurance/Quality Program (“QA/QP“) governing the extraction, manufacturing and quality control of Thykamine™.

Importantly, this independent third-party oversight will extend beyond method validation. Chromak Research Inc. and Pacific BioLabs are expected to continue to perform their respective HPLC-MS chemical characterisation and U-937 cell-based potency testing on future Thykamine™ production batches. This ongoing external testing is designed to provide independent verification of both the chemical consistency and biological activity of Thykamine™ throughout future manufacturing.

“This approach is particularly relevant to botanical drug development because U.S. Food and Drug Administration (“FDA“) recognizes that chemical characterisation of complex botanical products may need to be complemented by biological testing to help establish product quality and therapeutic consistency. The integration of these validated technologies directly into our quality-controlled extraction process represents an important step in the maturation of Thykamine™ as a pharmaceutical product”, said Dr André Boulet, PhD, President & CEO of Devonian.

“Ultimately, manufacturing reproducibility is also about patients. As Thykamine™ advances through clinical development, we want confidence that the product administered from one manufacturing batch to another is produced according to defined and reproducible chemical and biological quality standards”, added Dr Boulet.

NMR spectroscopy is additionally used as an orthogonal analytical characterisation tool to assess the overall chemical reproducibility of the botanical extract providing an additional measure of the consistency achieved through Devonian’s proprietary extraction process. To date, NMR analyses have demonstrated greater than 98% reproducibility from batch to batch, further supporting the high degree of chemical consistency achieved across independently manufactured Thykamine™ production batches.

Together, these complementary analytical and biological quality-control technologies provide a multi-layered framework for assessing Thykamine™ batch consistency, combining chemical fingerprinting, orthogonal structural characterisation and biological potency testing, supported by independent third-party validation and ongoing external testing.

“We believe these developments represent an important advancement in the pharmaceutical development and manufacturing control of Thykamine™, which should help pave the way toward regulatory and commercial acceptance,” concluded Dr. Boulet.

Addressing a Fundamental Challenge in Botanical Drug Development

Botanical drugs differ fundamentally from conventional single-molecule pharmaceuticals. They are generally complex mixtures containing multiple chemical constituents, and their biological activity may result from the contribution and interaction of multiple components rather than from a single identified molecule.

The FDA recognizes these characteristics and, through its Botanical Drug Development: Guidance for Industry (“BDDG“), addresses the need for appropriate chemical characterisation of botanical drugs.¹

The FDA’s BDDG also recognises that chemical testing alone may not always be sufficient to ensure quality and therapeutic consistency. In such circumstances, the FDA recommends that an appropriate biological assay be included in the product’s control strategy. The FDA further indicates that a biological assay reflecting the drug’s known or intended mechanism of action is preferred and that appropriate controls should be incorporated to demonstrate reproducible and predictable assay performance.

Building a Pharmaceutical-Grade Botanical Drug Platform

Devonian has developed a proprietary extraction and manufacturing process for Thykamine™, a complex pharmaceutical-grade botanical extract being investigated for its anti-inflammatory, antioxidant, immunomodulatory and anti-fibrotic properties.

The Company’s manufacturing strategy combines controlled sourcing of botanical raw materials, standardised extraction conditions, analytical characterisation, biological potency testing and pharmaceutical quality systems.

The combination of validated HPLC-MS chemical fingerprinting, NMR characterisation, and validated U-937 cell-based potency testing represents another step toward establishing a comprehensive manufacturing and quality-control platform capable of supporting Devonian’s expanding clinical development programmes and potential future regulatory submissions.